WO2011093811A3 - Pharmaceutical preparations comprising formoterol and fluticasone - Google Patents

Pharmaceutical preparations comprising formoterol and fluticasone Download PDF

Info

Publication number
WO2011093811A3
WO2011093811A3 PCT/TR2011/000013 TR2011000013W WO2011093811A3 WO 2011093811 A3 WO2011093811 A3 WO 2011093811A3 TR 2011000013 W TR2011000013 W TR 2011000013W WO 2011093811 A3 WO2011093811 A3 WO 2011093811A3
Authority
WO
WIPO (PCT)
Prior art keywords
formoterol
fluticasone
pharmaceutical preparations
pharmaceutical compositions
capsule
Prior art date
Application number
PCT/TR2011/000013
Other languages
French (fr)
Other versions
WO2011093811A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00682A external-priority patent/TR201000682A2/en
Priority claimed from TR2010/00728A external-priority patent/TR201000728A2/en
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093811A2 publication Critical patent/WO2011093811A2/en
Publication of WO2011093811A3 publication Critical patent/WO2011093811A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to pharmaceutical compositions in dry powder form comprising formoterol and fluticasone and/or their pharmaceutically acceptable derivatives as active agents, and capsule and blister forms containing these pharmaceutical compositions so as to be used in treatment of respiratory tract diseases.
PCT/TR2011/000013 2010-01-29 2011-01-28 Pharmaceutical preparations comprising formoterol and fluticasone WO2011093811A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00682A TR201000682A2 (en) 2010-01-29 2010-01-29 Pharmaceutical preparations containing formoterol and fluticasone.
TR2010/00682 2010-01-29
TR2010/00728A TR201000728A2 (en) 2010-02-02 2010-02-02 Pharmaceutical preparations containing formoterol and fluticasone.
TR2010/00728 2010-02-02

Publications (2)

Publication Number Publication Date
WO2011093811A2 WO2011093811A2 (en) 2011-08-04
WO2011093811A3 true WO2011093811A3 (en) 2012-02-23

Family

ID=43899577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000013 WO2011093811A2 (en) 2010-01-29 2011-01-28 Pharmaceutical preparations comprising formoterol and fluticasone

Country Status (1)

Country Link
WO (1) WO2011093811A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048587A1 (en) * 1999-02-18 2000-08-24 Novartis Ag Combinations of formoterol and fluticasone propionate for asthma
WO2001070198A1 (en) * 2000-03-20 2001-09-27 Dura Pharmaceuticals, Inc. Stabilized dry powder formulations
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048587A1 (en) * 1999-02-18 2000-08-24 Novartis Ag Combinations of formoterol and fluticasone propionate for asthma
WO2001070198A1 (en) * 2000-03-20 2001-09-27 Dura Pharmaceuticals, Inc. Stabilized dry powder formulations
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics

Also Published As

Publication number Publication date
WO2011093811A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
JP2010132695A5 (en)
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
IL216741A (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
EA201491479A1 (en) DERIVATIVES OF LUPANOV TRITERPENOIDS AND THEIR PHARMACEUTICAL APPLICATIONS
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
TR201000681A2 (en) Dry powder formulations inhaled.
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
TR201000733A2 (en) Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate.
WO2012047182A3 (en) Single dose dry powder inhalation device
MX2015015132A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
EA201170117A1 (en) ANTIALLERGICAL BIOPOLYMERS OF MARINE ORIGIN
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093814A3 (en) A pharmaceutical combination comprising formoterol and ciclesonide
WO2012030308A3 (en) Formulation comprising cellobiose
WO2011037549A3 (en) Dry powder formulation of tiotropium carried in blister strip

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11706647

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11706647

Country of ref document: EP

Kind code of ref document: A2